Literature DB >> 26223918

Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients.

Xiao-Hui Wang1,2, Xin Zhang2, Chang-Jun Mu2, Yong He2, Qing-Ping Peng2, Guo-Sheng Yang2, Ming-Mei Li2, Duan Liu2, Jing Li2, Guo-Hua Ding3.   

Abstract

The effect of lanthanum carbonate on abdominal aortic calcification (AAC) in the elderly maintenance hemodialysis (MHD) patients was investigated. Fifty-four cases subjected to routine MHD complicated with skin pruritus admitted to our hospital were selected and randomly divided into case group (n=28) and control group (n=26). The control group was given routine MHD alone. The case group was given lanthanum carbonate additionally on the basis of routine MHD. The changes of itching degrees at first and third month, and serum calcium, phosphorus, calcium-phosphorus products, intact parathyroid hormone (iPTH) levels and AAC scores at third month after treatments were compared between the two groups. The correlation between calcium-phosphorus products and AAC scores was also analyzed. There was no significant difference in the baseline of blood urea nitrogen (BUN), serum creatinine (Scr), uric acid, albumin, hemoglobin, C reactive protein (CRP), low density lipoprotein (LDL), high density lipoprotein (HDL), triglyceride, total cholesterol between case group and control group (P>0.05 for all). There was also no significant difference in the baseline itching scores between the case group and the control group (P>0.05). At 1st and 3rd month after treatment, the itching scores in the case group were 14.2 ± 3.2 and 10.5 ± 2.3, respectively, which were significantly lower than the baseline and those in the control group (P<0.05 for all). At 1st and 3rd month after treatment, the itching scores in the control group were 23.6 ± 5.9 and 24.8 ± 6.3, respectively, which were significantly higher than the baseline (P<0.05). There was no significant difference in the baseline of serum calcium, phosphorus, calcium-phosphorus products, iPTH levels between the case group and control group (P>0.05). At 3rd month after treatment, serum phosphorus, calcium-phosphorus products and iPTH levels in the case group were decreased significantly as compared with the baseline (P<0.05), and the serum calcium, phosphorus, calcium-phosphorus products, and iPTH levels were statistically decreased as compared with those in the control group (P<0.05). The AAC scores showed statistically significant difference between the case group and the control group (P<0.05). The serum phosphorus and AAC scores showed a positive correlation in both two groups. It was suggested that the administration of lanthanum carbonate in the elderly MHD patients can effectively relieve itching, and simultaneously reduce serum phosphorus and iPTH levels, resulting in the attenuation of vascular calcification.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26223918     DOI: 10.1007/s11596-015-1461-y

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  22 in total

Review 1.  An update on pruritus associated with CKD.

Authors:  Tejesh S Patel; Barry I Freedman; Gil Yosipovitch
Journal:  Am J Kidney Dis       Date:  2007-07       Impact factor: 8.860

2.  Appraising stroke risk in maintenance hemodialysis patients: a large single-center cohort study.

Authors:  Albert Power; Kakit Chan; Seema K Singh; David Taube; Neill Duncan
Journal:  Am J Kidney Dis       Date:  2011-09-23       Impact factor: 8.860

Review 3.  Chronic pruritus--pathogenesis, clinical aspects and treatment.

Authors:  M Metz; S Ständer
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-09-15       Impact factor: 6.166

4.  A longitudinal study of uremic pruritus in hemodialysis patients.

Authors:  Vandana S Mathur; Jill Lindberg; Michael Germain; Geoffrey Block; James Tumlin; Mark Smith; Mandeep Grewal; Dawn McGuire
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-17       Impact factor: 8.237

5.  Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study.

Authors:  Francis Verbeke; Wim Van Biesen; Eero Honkanen; Björn Wikström; Per Bruno Jensen; Jean-Marie Krzesinski; Merete Rasmussen; Raymond Vanholder; Pieter L Rensma
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-09       Impact factor: 8.237

6.  The case for routine parathyroid hormone monitoring.

Authors:  Stuart M Sprague; Sharon M Moe
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-04       Impact factor: 8.237

Review 7.  Use of phosphate binders in chronic kidney disease.

Authors:  Markus Ketteler; Patrick H Biggar
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-07       Impact factor: 2.894

8.  Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate.

Authors:  Ismail A Mohammed; Alastair J Hutchison
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

9.  Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms.

Authors:  Karthik Ramakrishnan; T Christopher Bond; Ami Claxton; Vipan C Sood; Maria Kootsikas; Wendy Agnese; Scott Sibbel
Journal:  Int J Nephrol Renovasc Dis       Date:  2013-12-19

10.  Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.

Authors:  Pablo Ureña-Torres; Dominique Prié; Karim Keddad; Peter Preston; Paul Wilde; Hong Wan; J Brian Copley
Journal:  BMC Nephrol       Date:  2014-05-05       Impact factor: 2.388

View more
  3 in total

1.  Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials.

Authors:  Chelsea Xu; Edward R Smith; Mark K Tiong; Irene Ruderman; Nigel D Toussaint
Journal:  J Am Soc Nephrol       Date:  2022-03-01       Impact factor: 14.978

2.  Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).

Authors:  Marinella Ruospo; Suetonia C Palmer; Patrizia Natale; Jonathan C Craig; Mariacristina Vecchio; Grahame J Elder; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2018-08-22

Review 3.  Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.

Authors:  Lijuan Zhao; An Liu; Guoshuang Xu
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.